Background
==========

Riociguat, an oral soluble guanylate cyclase stimulator, is under investigation for pulmonary hypertension treatment. Cytochrome P450 (CYP)-mediated oxidative metabolism is one of the major riociguat clearance pathways. The pharmacokinetic interactions between riociguat and ketoconazole (multi-pathway CYP and P-glycoprotein/breast cancer resistance protein \[P-gp/BCRP\] inhibitor), clarithromycin (CYP3A4 inhibitor), and midazolam (CYP3A4 substrate) were investigated.

Methods
=======

Three open-label, randomized, crossover studies were performed in healthy males. In the first study, subjects received riociguat 0.5 mg ± ketoconazole (4-day pretreatment with once-daily \[od\] ketoconazole 400 mg, then riociguat + 1 dose of ketoconazole 400 mg) (n=16). In the second study, subjects received riociguat 1 mg ± clarithromycin (4-day pretreatment with twice-daily clarithromycin 500 mg, then riociguat + 1 dose of clarithromycin 500 mg) (n=14). In the third study, subjects received three-times daily (tid) riociguat 2.5 mg for 3 days, then 1 day of riociguat 2.5 mg tid ± midazolam 7.5 mg (n=24). Pharmacokinetic parameters, safety, and tolerability were assessed.

Results
=======

Pre- and co-treatment with ketoconazole increased riociguat mean AUC by 150% and mean C~max~ by 46% (Figure [1](#F1){ref-type="fig"}; Table [1](#T1){ref-type="table"}). Pre- and co-treatment with clarithromycin increased riociguat AUC by 41% without significantly increasing C~max~ (Figure [2](#F2){ref-type="fig"}; Table [1](#T1){ref-type="table"}). Riociguat pre- and co-treatment did not significantly alter the AUC or C~max~ of midazolam (Figure [3](#F3){ref-type="fig"}; Table [2](#T2){ref-type="table"}). In the ketoconazole study, adverse events (AEs) were reported in 4 (25%), 6 (38%), and 5 (31%) subjects treated with riociguat alone, riociguat + ketoconazole, and ketoconazole alone, respectively. In the clarithromycin study, AEs were reported in 4 (29%), 9 (64%), and 9 (64%) subjects treated with riociguat alone, riociguat + clarithromycin, and clarithromycin alone, respectively. In the midazolam study, AEs were reported in 20 (87%), 11 (48%), and 6 (27%) subjects treated with riociguat alone, riociguat + midazolam, and midazolam alone, respectively. The most common AEs with riociguat ± ketoconazole, clarithromycin, and midazolam across the three studies were headache and dyspepsia. One serious AE was reported in the midazolam study (elevated creatine phosphokinase; not drug-related).

###### 

The effects of ketoconazole and clarithromycin on riociguat pharmacokinetics (geometric means and coefficients of variation)

                  Riociguat/ketoconazole study   Riociguat/clarithromycin study                                         
  --------------- ------------------------------ -------------------------------- ------- ------ ------- ------ ------- ------
  AUC (µg·h/L)    81.9                           78.6                             204.9   44.9   171.1   97.0   240.0   88.9
  C~max~ (µg/L)   9.4                            29.9                             13.7    19.3   20.8    37.7   21.6    33.9
  t~1/2~ (h)      7.3                            78.5                             9.2     57.1   6.4     77.1   7.9     54.6
  CL/f (L/h)      6.1                            78.6                             2.4     44.9   5.8     97.0   4.2     88.9

AUC, area under plasma concentration--time curve; CL/f, total riociguat clearance from plasma; C~max~, maximum riociguat plasma concentration; CV, coefficient of variation; GM, geometric mean; t~1/2~, elimination half-life.

###### 

The effects of riociguat on midazolam pharmacokinetics (geometric means and coefficients of variation)

  Midazolam/riociguat study                                                                   
  --------------------------- ------------------ ------------------------------------- ------ ------
                              Midazolam (n=22)   Midazolam + riociguat 2.5 mg (n=22)          
                                                                                              
  Parameter                   GM                 %CV                                   GM     %CV
                                                                                              
  AUC (µg·h/L)                91.1               34.3                                  98.2   37.0
  C~max~ (µg/L)               29.0               45.1                                  29.5   41.5
  t~1/2~ (h)                  4.5                35.9                                  4.3    34.9

AUC, area under plasma concentration--time curve; C~max~, maximum riociguat plasma concentration; CV, coefficient of variation; GM, geometric mean; t~1/2~, elimination half-life.
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Conclusions
===========

The combined use of riociguat with multi-pathway inhibitors such as anti-mycotics (eg ketoconazole) or HIV protease inhibitors should be avoided due to the expected increase in riociguat exposure. General dose adaptation for patients with co-medication inhibiting the CYP3A4 pathway or the P-gp/BCRP-mediated excretion of riociguat, beyond the dose titration concept for riociguat, is not deemed necessary. Riociguat ± ketoconazole, clarithromycin, or midazolam was generally well tolerated.
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